<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-135519" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fibrodysplasia Ossificans Progressiva</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Agrawal</surname>
            <given-names>Udit</given-names>
          </name>
          <aff>All India Institute of Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiwari</surname>
            <given-names>Vivek</given-names>
          </name>
          <aff>Apollo Sage Hospital, Bhopal, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Udit Agrawal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vivek Tiwari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-135519.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Fibrodysplasia ossificans progressiva is a rare genetic disorder that causes significant disability and morbidity. In this disorder, heterotopic ossification starts in the first decade of life, and a majority of such cases develop inflammatory painful soft tissue swellings. This disability progresses from upper to lower end, proximal to the distal end, and a dorsal to ventral side, i.e., from neck, spine, shoulders to elbow, knee, hip, jaw to wrists, and ankle. The wrists, ankles, elbows, knees, hips, and jaw gradually get involved till 40 years of age. There is no definitive management for this life-threatening disorder to date, and various new drugs are being tested in clinical trials. This activity reviews the presentation, evaluation, and management of fibrodysplasia ossificans progressiva and highlights the role of the interprofessional team in evaluating and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of fibrodysplasia ossificans progressiva.</p></list-item><list-item><p>Review the common presentation of a patient with fibrodysplasia ossificans progressiva.</p></list-item><list-item><p>Identify the various investigations required for diagnosing fibrodysplasia ossificans progressiva.</p></list-item><list-item><p>Explain the current treatment options for patients with fibrodysplasia ossificans progressiva, along with the complications anticipated.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=135519&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=135519">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-135519.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Fibrodysplasia ossificans progressiva is described as a rare genetic disorder characterized by the organization of heterotopic hard tissues within the soft tissues, such as ligaments, tendons, and skeletal muscle.<xref ref-type="bibr" rid="article-135519.r1">[1]</xref><xref ref-type="bibr" rid="article-135519.r2">[2]</xref><xref ref-type="bibr" rid="article-135519.r3">[3]</xref>&#x000a0;It comes under the category of an autosomal dominant disorder. The tissue formed in such patients is not just the mineralized calcium phosphate, but it resembles the new bone formation by osteoblast cells via endochondral ossification. Most of the patients who are suffering from Fibrodysplasia ossificans progressiva can move their joints normally at the time of birth, but disability arises in various joints when they reach their 30&#x02019;s because gradually hetero&#x000ad;topic bones fuse and result in bridge formation with normal bones.<xref ref-type="bibr" rid="article-135519.r4">[4]</xref>&#x000a0;Injury to soft tissues can lead to acute heterotopic bone formation in such patients hence invasive procedures, such as injection, surgical operation, and biopsy, are contraindicated.<xref ref-type="bibr" rid="article-135519.r3">[3]</xref><xref ref-type="bibr" rid="article-135519.r5">[5]</xref><xref ref-type="bibr" rid="article-135519.r6">[6]</xref></p>
        <p>Making a diagnosis of fibrodysplasia ossificans progressiva was difficult for a long time as there were no reliable biomarkers for such cases&#x000a0;that could be evaluated in urine or peripheral blood. The pathogenesis found in such patients is the gain of function mutation in the ACVR1/ALK2 gene located over chromosome 2 and the involvement of the bone morphogenetic proteins (BMP) signaling pathway.<xref ref-type="bibr" rid="article-135519.r7">[7]</xref>&#x000a0;The BMPs lead to the formation of heterotopic bone in the soft tissues.<xref ref-type="bibr" rid="article-135519.r6">[6]</xref>&#x000a0;The most common sites affected are the shoulders, neck, and spine. The median age of survival is roughly around 40 years.<xref ref-type="bibr" rid="article-135519.r8">[8]</xref>&#x000a0;Death occurs in such cases primarily due to thoracic insufficiency syndrome and related complications. PCR is the main diagnostic modality for the analysis of genetic mutation in FOP.<xref ref-type="bibr" rid="article-135519.r3">[3]</xref><xref ref-type="bibr" rid="article-135519.r5">[5]</xref></p>
      </sec>
      <sec id="article-135519.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Fibrodysplasia ossificans progressiva is a typical monogenic disorder with the recurrent heterozygous gain of function mutation in the ACVR1/ALK2 gene located on chromosome 2, both in the sporadic and inherited cases, and involves the BMP (bone morphogenetic proteins) signaling pathway. This ACVR1/ALK2 gene encodes for a transmembrane serine/threonine (ser/thr) kinase receptor ALK2, which binds with the BMPs present in the bone matrix.<xref ref-type="bibr" rid="article-135519.r9">[9]</xref>&#x000a0;</p>
        <p>These BMPs induce the development of heterotopic bone in the skeletal muscle. The majority of cases of typical&#x000a0;Fibrodysplasia ossificans progressiva show a similar genetic mutation which consists of a change of nucleotide in the codon at position 617 (guanine-&#x0003e;adenine) in the ACVR1/ALK2 gene.<xref ref-type="bibr" rid="article-135519.r3">[3]</xref><xref ref-type="bibr" rid="article-135519.r8">[8]</xref>&#x000a0;It results in a substitution mutation in the codon at a position 206 (arginine-&#x0003e;histidine) within the ALK2 protein.<xref ref-type="bibr" rid="article-135519.r10">[10]</xref>&#x000a0;</p>
        <p>Some additional mutations are also noticed in exons 4 through 7 within the ACVR1/ALK2 gene, which results in a change in the expression of two domains, including Ser/Thr kinase and the glycine/serine-rich. Both of these domains play an important role in intracellular signaling.<xref ref-type="bibr" rid="article-135519.r6">[6]</xref><xref ref-type="bibr" rid="article-135519.r7">[7]</xref></p>
      </sec>
      <sec id="article-135519.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Fibrodysplasia ossificans progressiva shows an incidence of approximately one patient per 2 million people worldwide and is not determined by any race, gender, or geographical distribution.<xref ref-type="bibr" rid="article-135519.r3">[3]</xref><xref ref-type="bibr" rid="article-135519.r6">[6]</xref></p>
      </sec>
      <sec id="article-135519.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The gain of function mutation in the ACVR1/ALK2 gene, which encodes for ALK2 kinases, induces signal transduction by ALK2 in response to ligand binding.<xref ref-type="bibr" rid="article-135519.r7">[7]</xref><xref ref-type="bibr" rid="article-135519.r11">[11]</xref>&#x000a0;The extracellular domain of ALK2 (a type I receptor) binds with both the TGF-&#x003b2; family ligands (such as BMP-6, BMP-7, BMP9, and activin B) and with one of the type II receptors [such as BMP receptor type II (BMPR-II), activin receptor type IIA (Acta-IIA) and activin receptor type IIB (Acta-IIB)].<xref ref-type="bibr" rid="article-135519.r9">[9]</xref>&#x000a0;</p>
        <p>Since these type II receptors are constitutively active ser/thr kinases, phosphorylation of ALK2 occurs at the GS domain consisting of glycine and serine residues in the ternary complex formed by the ligand binding to ALK2 at the cell membrane. This phosphorylated ALK2, in turn, activates the kinase activity and phosphorylates serine and threonine residues in the downstream substrates such as SMAD1, SMAD5, and Smad8/9.<xref ref-type="bibr" rid="article-135519.r10">[10]</xref><xref ref-type="bibr" rid="article-135519.r12">[12]</xref>&#x000a0;</p>
        <p>These phosphorylated Smad proteins bind to specific DNA sequences and regulate the transcription of the target genes in the nucleus and result in the heterotopic ossification seen in patients with fibrodysplasia ossificans progressiva. Thus, all these mutations induce intracellular signaling where ALK2 acts as the type 1 receptor in co-operation with the type II receptors.<xref ref-type="bibr" rid="article-135519.r5">[5]</xref><xref ref-type="bibr" rid="article-135519.r6">[6]</xref></p>
      </sec>
      <sec id="article-135519.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Early lesions of fibrodysplasia ossificans progressiva show a rapid and destructive inflammatory stage characterized by an intense mononuclear and perivascular infiltration by macrophages, mast cells, and lymphocytes. The subsequent migration of these inflammatory cells into the affected skeletal muscle causes its death.<xref ref-type="bibr" rid="article-135519.r13">[13]</xref>&#x000a0;This is followed by an intense fibroproliferative phase characterized by angiogenesis, neovascularity, and a very high density of mast cells.<xref ref-type="bibr" rid="article-135519.r14">[14]</xref>&#x000a0;</p>
        <p>Early lesions of this phase are histologically similar to aggressive juvenile fibromatosis and can not be distinguished. As these lesions mature, the fibroproliferative tissue is converted into cartilage by the process of avascular condensation. This is followed by the final phase of revascularization with osteogenesis in a characteristic process of heterotopic ossification forming new ossicles of heterotopic bone, which appear histologically similar to the mature lamellar bone and often contain marrow elements.<xref ref-type="bibr" rid="article-135519.r14">[14]</xref><xref ref-type="bibr" rid="article-135519.r15">[15]</xref>&#x000a0;</p>
        <p>This heterotopic bone formation resembles bone formation in embryonic skeletal development and postnatal fracture healing, except for the lack of inflammation in the primary skeletal formation. The fibroproliferative, chondrogenic and osteogenic stages of heterotopic ossification are characterized by multipotent stem-like cells of vascular origin while the late osteogenic phase is characterized by inflammatory cells of hematopoietic origin. All these stages are seen in an active Fibrodysplasia ossificans progressiva lesion, thus suggesting different rates of maturation of different regions of the lesion.<xref ref-type="bibr" rid="article-135519.r16">[16]</xref></p>
      </sec>
      <sec id="article-135519.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>More than 90% of affected individuals show malformations of the great toes at birth but otherwise appear normal with normal joint mobility. In the first decade of life, heterotopic ossification starts, and a majority of the cases of fibrodysplasia ossificans progressiva develop inflammatory soft tissue swellings which are episodic, painful, and may show flare-ups.<xref ref-type="bibr" rid="article-135519.r5">[5]</xref>&#x000a0;</p>
        <p>Joint disability sets in the third decade of life due to the fusion of the heterotopic bones formed in the soft tissue with the normal bones, thus fixing the joints.<xref ref-type="bibr" rid="article-135519.r3">[3]</xref>&#x000a0;The most frequently affected sites are the neck, spine, and shoulders (more than 80% of cases in patients less than 15 years of age). The wrists, ankles, elbows, knees, hips, and jaw gradually get involved till 40 years of age. This disability progresses from upper to lower end, proximal to the distal end, and a dorsal to ventral side, i.e., from neck, spine, shoulders to elbow, knee, hip, jaw to wrists, and ankle. Thus, these patients become wheelchair-bound by the third decade of life, requiring lifelong assistance for daily activities. The median age of survival in these patients is approximately 40 years.<xref ref-type="bibr" rid="article-135519.r5">[5]</xref></p>
      </sec>
      <sec id="article-135519.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of Fibrodysplasia ossificans progressiva is made mainly by genetic mutations analysis of the involved gene by doing Sanger sequencing of the PCR products.<xref ref-type="bibr" rid="article-135519.r8">[8]</xref>&#x000a0;Routine biochemical evaluations of the heterotopic bone seen in Fibrodysplasia ossificans progressiva are usually similar to that of the normal bone, so these are distinguished based on the location of the heterotopic bone. During the disease flare-ups, the serum alkaline phosphatase activity and ESR may be increased along with the elevated urinary basic fibroblast growth factor levels.<xref ref-type="bibr" rid="article-135519.r5">[5]</xref><xref ref-type="bibr" rid="article-135519.r9">[9]</xref>&#x000a0;</p>
        <p>These increased urinary basic fibroblast growth factor levels coincide with the pre-osseous angiogenic phase of early fibroproliferative lesions. Another important diagnostic tool is Imaging analysis. Plain X-rays can reveal abnormal osteogenesis after heterotopic ossification manifests. CT scan can also show lesions with typical heterotopic ossifications.<xref ref-type="bibr" rid="article-135519.r17">[17]</xref>&#x000a0;MRI can reveal preosseous lesions, which appear as soft tissue swelling and skeletal malformations. Diagnosis of fibrodysplasia ossificans progressiva can not be made prenatally.</p>
      </sec>
      <sec id="article-135519.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no single effective treatment option available for Fibrodysplasia ossificans progressiva.<xref ref-type="bibr" rid="article-135519.r6">[6]</xref>&#x000a0;Although symptomatic management for flare-ups can be provided with a short duration of high-dose corticosteroids like prednisone, the frequent use of corticosteroids is not advised. Mast cell inhibitors, NSAIDS, amino bisphosphonates, and COX-2 inhibitors are used for treating later flare-ups.<xref ref-type="bibr" rid="article-135519.r18">[18]</xref><xref ref-type="bibr" rid="article-135519.r19">[19]</xref>&#x000a0;</p>
        <p>Muscle relaxants can be used in small doses for muscle spasms. Another potential treatment option is to inhibit the activity of the ACVR1/ALK2 gene-related pathway, which inhibits abnormal bone formation. The other strategy would be to inhibit osteoblastic progenitor cell activity, which results in hindering the microenvironment for heterotopic ossificans. With the increasing understanding of the pathogenesis of fibrodysplasia ossificans progressiva, new potential drug targets have been discovered.<xref ref-type="bibr" rid="article-135519.r20">[20]</xref><xref ref-type="bibr" rid="article-135519.r21">[21]</xref>&#x000a0;</p>
        <p>Many drugs, such as imatinib, a human anti-activin A-neutralizing antibody, dorsomorphin, palovarotene, rapamy&#x000ad;cin, are in clinical trials, and suitable drugs may be available in the coming future concerning the better understanding of the mechanism of onset of fibrodysplasia ossificans progressiva.<xref ref-type="bibr" rid="article-135519.r3">[3]</xref>&#x000a0;Surgery is not generally preferred for such patients.<xref ref-type="bibr" rid="article-135519.r6">[6]</xref></p>
      </sec>
      <sec id="article-135519.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The common differential diagnosis of fibrodysplasia ossificans progressiva includes isolated congenital malformations, juvenile bunions, sarcoma, desmoid tumor, aggressive juvenile fibromatosis, lymphedema.</p>
      </sec>
      <sec id="article-135519.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Fibrodysplasia ossificans progressiva has a poor prognosis due to associated complications, including pneumonia and right-sided heart failure.&#x000a0; Death in these cases occurs due mainly to thoracic insufficiency syndrome and complications related to it.<xref ref-type="bibr" rid="article-135519.r3">[3]</xref><xref ref-type="bibr" rid="article-135519.r5">[5]</xref><xref ref-type="bibr" rid="article-135519.r6">[6]</xref></p>
      </sec>
      <sec id="article-135519.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Common complications associated with this disease include respiratory system infection, joint disabilities, cardiopulmonary complications (thoracic insufficiency syndrome, right-side congestive heart failure), submandibular swelling, temporomandibular joint ankylosis conductive loss of hearing.<xref ref-type="bibr" rid="article-135519.r5">[5]</xref><xref ref-type="bibr" rid="article-135519.r6">[6]</xref><xref ref-type="bibr" rid="article-135519.r8">[8]</xref></p>
      </sec>
      <sec id="article-135519.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The patients presenting with significant toe deformities associated with fibrodysplasia ossificans progressiva should be promptly identified and evaluated for the disease. As this disorder causes significant morbidity and early mortality, early identification can help prolong the survival of such patients. Once the disorder is diagnosed, the patients should avoid invasive procedures like injections or surgery, which may trigger the new bone formation. Also, proper rehabilitation for joint deformities and stiffness can help in getting the best functional outcomes.</p>
      </sec>
      <sec id="article-135519.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The evaluation of fibrodysplasia ossificans progressiva begins with clinical suspicion for this life-threatening disease. As such, pediatricians and neonatologists should be adequately informed about the clinical signs and the evaluation strategies for this condition. Also, once the condition is diagnosed, physicians and pediatricians can help in the symptomatic management of the inflammatory disease activity. Also, physiotherapist opinion should be sought&#x000a0;regarding appropriate&#x000a0;means for managing joint stiffness and deformities.</p>
      </sec>
      <sec id="article-135519.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=135519&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=135519">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/fibrodysplasia-ossificans-progressiva-stone-man-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=135519">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/135519/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=135519">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-135519.s16">
        <fig id="article-135519.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Skelton of an individual who suffered from fibrodysplasia ossificans progressiva. Created by Joh-co on Wiki Commons, used under Attribution-ShareAlike 3.0 Unported (CC BY-SA 3.0), https://creativecommons.org/licenses/by-sa/3.0/</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Fibrodysplasia_ossificans_progressiva" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-135519.s17">
        <title>References</title>
        <ref id="article-135519.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Chakkalakal</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis.</article-title>
            <source>Dis Model Mech</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>756</fpage>
            <page-range>756-62</page-range>
            <pub-id pub-id-type="pmid">23115204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katagiri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsukamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuratani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.</article-title>
            <source>Bone</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>109</volume>
            <fpage>241</fpage>
            <page-range>241-250</page-range>
            <pub-id pub-id-type="pmid">28754575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katagiri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsukamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakachi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuratani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recent Topics in Fibrodysplasia Ossificans Progressiva.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>331</fpage>
            <page-range>331-338</page-range>
            <pub-id pub-id-type="pmid">30229572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shafritz</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Zasloff</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Taub</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Muenke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva.</article-title>
            <source>N Engl J Med</source>
            <year>1996</year>
            <month>Aug</month>
            <day>22</day>
            <volume>335</volume>
            <issue>8</issue>
            <fpage>555</fpage>
            <page-range>555-61</page-range>
            <pub-id pub-id-type="pmid">8678932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pignolo</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.</article-title>
            <source>Pediatr Endocrinol Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>10 Suppl 2</volume>
            <issue>0 2</issue>
            <fpage>437</fpage>
            <page-range>437-48</page-range>
            <pub-id pub-id-type="pmid">23858627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Luan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.</article-title>
            <source>Intractable Rare Dis Res</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>242</fpage>
            <page-range>242-248</page-range>
            <pub-id pub-id-type="pmid">29259851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>DMP</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification.</article-title>
            <source>Stem Cell Res Ther</source>
            <year>2019</year>
            <month>Jan</month>
            <day>11</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">30635039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Brasi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gaeta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Liso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Acquaviva</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martemucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mastrominico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Rocco</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis.</article-title>
            <source>Genes (Basel)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>30</day>
            <volume>12</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">34440363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Traberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gintautiene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bocciardi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.</article-title>
            <source>Mol Genet Genomic Med</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>e1774</fpage>
            <pub-id pub-id-type="pmid">34347384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>BMP and mTOR signaling in heterotopic ossification: Does their crosstalk provide therapeutic opportunities?</article-title>
            <source>J Cell Biochem</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>120</volume>
            <issue>8</issue>
            <fpage>12108</fpage>
            <page-range>12108-12122</page-range>
            <pub-id pub-id-type="pmid">30989716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ventura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ikeya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bullock</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Ten Dijke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goumans</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sanchez-Duffhues</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.</article-title>
            <source>Biomedicines</source>
            <year>2021</year>
            <month>Feb</month>
            <day>19</day>
            <volume>9</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33669809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Twombly</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bangi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Malnic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Functional analysis of saxophone, the Drosophila gene encoding the BMP type I receptor ortholog of human ALK1/ACVRL1 and ACVR1/ALK2.</article-title>
            <source>Genetics</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>183</volume>
            <issue>2</issue>
            <fpage>563</fpage>
            <page-range>563-79, 1SI-8SI</page-range>
            <pub-id pub-id-type="pmid">19620392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Towler</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).</article-title>
            <source>Dev Dyn</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>251</volume>
            <issue>1</issue>
            <fpage>164</fpage>
            <page-range>164-177</page-range>
            <pub-id pub-id-type="pmid">34133058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hegyi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Shanahan</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification?</article-title>
            <source>J Pathol</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>201</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-8</page-range>
            <pub-id pub-id-type="pmid">12950027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Tabas</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Finkel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Zasloff</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The histopathology of fibrodysplasia ossificans progressiva. An endochondral process.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1993</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>220</fpage>
            <page-range>220-30</page-range>
            <pub-id pub-id-type="pmid">7678595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gannon</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Mast cell involvement in fibrodysplasia ossificans progressiva.</article-title>
            <source>Hum Pathol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>842</fpage>
            <page-range>842-8</page-range>
            <pub-id pub-id-type="pmid">11521229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warner</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Pignolo</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>De Cunto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Rocco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harnett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Genant</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Whole-body Computed Tomography Versus Dual Energy X&#x02011;ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.</article-title>
            <source>Calcif Tissue Int</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>109</volume>
            <issue>6</issue>
            <fpage>615</fpage>
            <page-range>615-625</page-range>
            <pub-id pub-id-type="pmid">34331548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simmons</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Botting</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hla</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.</article-title>
            <source>Pharmacol Rev</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-437</page-range>
            <pub-id pub-id-type="pmid">15317910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuetz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Christ-Crain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases.</article-title>
            <source>Spinal Cord</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>604</fpage>
            <page-range>604-10</page-range>
            <pub-id pub-id-type="pmid">15867938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaikuad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alfano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sanvitale</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Boergermann</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Triffitt</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>von Delft</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knaus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bullock</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.</article-title>
            <source>J Biol Chem</source>
            <year>2012</year>
            <month>Oct</month>
            <day>26</day>
            <volume>287</volume>
            <issue>44</issue>
            <fpage>36990</fpage>
            <page-range>36990-8</page-range>
            <pub-id pub-id-type="pmid">22977237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135519.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hashizume</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hohjoh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fusaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Furuya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Era</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.</article-title>
            <source>Stem Cells</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>2437</fpage>
            <page-range>2437-49</page-range>
            <pub-id pub-id-type="pmid">22949078</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
